319 related articles for article (PubMed ID: 35486976)
1. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.
Wang P; Ni J; Chu YY; Chen QQ; Wu GC; Fang Y; Chen C; Zhang RD; Jiang LQ; Zhao Y; Fang X; He J; Wang DG; Wang GH; Pan HF
Biomed Pharmacother; 2022 Jun; 150():112997. PubMed ID: 35486976
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination.
Izmirly PM; Kim MY; Samanovic M; Fernandez-Ruiz R; Ohana S; Deonaraine KK; Engel AJ; Masson M; Xie X; Cornelius AR; Herati RS; Haberman RH; Scher JU; Guttmann A; Blank RB; Plotz B; Haj-Ali M; Banbury B; Stream S; Hasan G; Ho G; Rackoff P; Blazer AD; Tseng CE; Belmont HM; Saxena A; Mulligan MJ; Clancy RM; Buyon JP
Arthritis Rheumatol; 2022 Feb; 74(2):284-294. PubMed ID: 34347939
[TBL] [Abstract][Full Text] [Related]
3. Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
Tang Q; Li F; Tian J; Kang J; He J
Clin Exp Med; 2023 Jun; 23(2):457-463. PubMed ID: 35612692
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series.
Zhao T; Shen J; Zhu Y; Tian X; Wen G; Wei Y; Xu B; Fu C; Xie Z; Xi Y; Li Z; Peng J; Wu Y; Tang X; Wan C; Pan L; Li Z; Qin D
Front Public Health; 2022; 10():875558. PubMed ID: 35548080
[TBL] [Abstract][Full Text] [Related]
5. Humoral and T Cell Response to SARS-CoV-2 Vaccination in Patients With Rheumatoid Arthritis.
Isnardi CA; Landi M; Cruces L; Maid P; Calle Montoro C; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; Correa MÁ; Cerda OL; Rosemffet MG; Carrizo Abarza V; Catalan Pellet S; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; De La Vega MC; Citera G; Pons-Estel GJ; Schneeberger EE
Arthritis Care Res (Hoboken); 2024 Jan; 76(1):120-130. PubMed ID: 37605835
[TBL] [Abstract][Full Text] [Related]
6. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.
Bartels LE; Ammitzbøll C; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Thomsen MK; Erikstrup C; Hauge EM; Troldborg A
Rheumatol Int; 2021 Nov; 41(11):1925-1931. PubMed ID: 34476603
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic.
Sjöwall J; Azharuddin M; Frodlund M; Zhang Y; Sandner L; Dahle C; Hinkula J; Sjöwall C
Front Immunol; 2021; 12():724047. PubMed ID: 34512651
[TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE.
Reynolds JA; Faustini SE; Tosounidou S; Plant T; Ubhi M; Gilman R; Richter AG; Gordon C
Lupus; 2023 Mar; 32(3):431-437. PubMed ID: 36631440
[TBL] [Abstract][Full Text] [Related]
9. Anti-agalactosyl IgG antibodies in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis.
Louthrenoo W; Kasitanon N; Wichainun R; Wangkaew S; Sukitawut W; Kuwata S; Takeuchi F
Clin Rheumatol; 2010 Mar; 29(3):241-6. PubMed ID: 20091076
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital.
Tariverdi M; Mohammadi H; Hassanzadeh F; Tamaddondar M
BMC Infect Dis; 2024 Feb; 24(1):253. PubMed ID: 38395759
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
12. Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination.
Zhao WM; Shi R; Wang P; He J; Chen Y; Feng YT; Pan HF; Wang DG
J Inflamm Res; 2022; 15():3467-3475. PubMed ID: 35726214
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
15. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
[TBL] [Abstract][Full Text] [Related]
16. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project.
Mageau A; Tchen J; Ferré VM; Nicaise-Roland P; Descamps D; Delory N; François C; Mendes C; Papo T; Goulenok T; Charles N; Sacré K
J Autoimmun; 2023 Jan; 134():102987. PubMed ID: 36563528
[TBL] [Abstract][Full Text] [Related]
17. Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Ammitzbøll C; Thomsen MK; Andersen JB; Jensen JMB; Bayarri-Olmos R; Garred P; Hermansen MF; Johannsen AD; Larsen ML; Mistegaard CE; Mikkelsen S; Nielsen L; Olesen R; Pérez-Alós L; Vils SR; Szabados F; Søgaard OS; Tolstrup M; Erikstrup C; Hauge EM; Troldborg A
Clin Exp Rheumatol; 2024 Jan; 42(1):157-165. PubMed ID: 37877429
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and risk of disease flare after a three-dose regimen with SARS-CoV-2 vaccination in patients with systemic lupus erythematosus: results from the prospective cohort study COVAC-SLE.
Larsen ES; Nilsson AC; Möller S; Voss AB; Johansen IS
Clin Exp Rheumatol; 2023 Mar; 41(3):676-684. PubMed ID: 35894059
[TBL] [Abstract][Full Text] [Related]
19. Isolation, Behavioral Changes, and Low Seroprevalence of SARS-CoV-2 Antibodies in Patients With Systemic Lupus Erythematosus or Rheumatoid Arthritis.
Ammitzbøll C; Andersen JB; Vils SR; Mistegaard CE; Mikkelsen S; Erikstrup C; Thomsen MK; Hauge EM; Troldborg A
Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1780-1785. PubMed ID: 34057311
[TBL] [Abstract][Full Text] [Related]
20. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Schmiedeberg K; Abela IA; Pikor NB; Vuilleumier N; Schwarzmueller M; Epp S; Pagano S; Grabherr S; Patterson AB; Nussberger M; Trkola A; Ludewig B; von Kempis J; Rubbert-Roth A
RMD Open; 2022 Oct; 8(2):. PubMed ID: 36288822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]